Crape Jasmine for Wound Healing, Skin, and Antimicrobial Claims

Every traditional use recorded for crape jasmine outside the garden is a topical one — root paste on skin eruptions, latex on wounds and toothache, leaf poultices on inflammation. That external focus turns out to be pharmacologically sensible in one specific way this page will make precise: the plant’s latex genuinely contains a family of enzymes capable of clotting and dissolving blood clots, which is a real, mechanistically coherent basis for a wound claim. It is also, for exactly the same chemical reason, why raw latex is not something to put on broken skin or near an eye. This page separates the real rat data on wound healing and inflammation from the antimicrobial claims that turn out, on inspection, to be evidence about something other than what they are usually cited for.

Table of Contents

  1. What Is Actually Being Claimed
  2. The Traditional Record: Root, Latex and Leaf
  3. The 2024 Wound-Healing Study
  4. The Latex Protease Story: One Mechanism, Two Directions
  5. Anti-Inflammatory Extract Data
  6. Antimicrobial Claims, Examined One by One
  7. Why Raw Latex Is Not a Wound Dressing
  8. What Would Actually Settle This
  9. Evidence Ledger for This Page
  10. Practical Guidance
  11. Key Research Papers
  12. Connections

What Is Actually Being Claimed

Four distinct claims travel under “crape jasmine is good for the skin,” and they deserve to be separated before any evidence gets attached to them.

  1. Wound healing — a cut, ulcer or burn closes faster or better with a plant preparation than without one. The only claim with a real, purpose-built animal study behind it.
  2. General anti-inflammatory skin action — redness, swelling and itching from rashes or eruptions are reduced. Supported by rodent oedema models using a topical route, which at least matches the traditional application.
  3. Antimicrobial protection — the plant fights the bacteria or fungi that infect skin, teeth or wounds. The most heterogeneous claim of the four, and the one where the evidence most often turns out to be about something other than the plant itself.
  4. Toothache and dental use — root chewed or applied for tooth pain. Overlaps partly with the antimicrobial claim through one specific modern study.

What follows takes each in turn, names the actual study behind it, and states plainly where a claim rests on the plant and where it rests on something else entirely — a nanoparticle, a drug-resistance assay, or a computer prediction that was never tested on a living organism.

The Traditional Record: Root, Latex and Leaf

The main topic page already lays out the regional traditional-use record in detail: root paste for skin disease and wounds in Indian folk practice, latex applied to wounds and (unsafely) to the eyes, root chewed for toothache, and broadly similar external uses recorded across Thailand, Vietnam, Cambodia, Malaysia and Indonesia. Two features of that record matter for reading the pharmacology that follows.

First, the traditional preparations are overwhelmingly root and latex, not leaf. Much of the modern laboratory work, by contrast, uses leaf extract, because leaves are easier to source in quantity for a laboratory study than root bark from a slow-growing ornamental shrub. That is a real part substitution in the sense the evidence doctrine on this site tracks — alkaloid and enzyme content is not uniform across plant parts, and a leaf-extract result does not automatically confirm what a root paste or latex application would do, or vice versa. Where a study used root or latex specifically, this page says so.

Second, nothing in the traditional record specifies a concentration, a preparation method beyond “paste” or “applied fresh,” or a duration of use. That absence is not a minor omission — it is precisely the gap the modern hydrogel study below tried to close, by standardising an extract into a measurable, reproducible dose for the first time in this plant’s recorded history.

Back to Table of Contents

The 2024 Wound-Healing Study

The single strongest piece of evidence for a wound-healing claim is recent, specific, and worth describing in full rather than gesturing at. In 2024, a Pune-based pharmacy research group published a formulation study in the Journal of Ayurveda and Integrative Medicine that took a standardised ethanolic extract of crape jasmine leaves, loaded it into a polyvinyl-alcohol hydrogel, and tested it across three separate wound models in Wistar rats — excision, incision, and burn, which is a more complete design than most single-model plant studies on this site have to work with.

The numbers were real and dose-related. In the excision model, by day twenty the lower-concentration hydrogel (0.5 mg/mL) produced 90.35% (±0.46) wound contraction and the higher concentration (1 mg/mL) produced 97.28% (±0.59), both significantly ahead of untreated and vehicle-only control groups. In the incision model, measured on day nine, treated wounds showed tensile strength of 191.16 g (±1.51) and 201.00 g (±1.29) at the two doses. In the burn model, both doses shortened the time to full epithelialisation and increased the rate of wound contraction. Histology of the treated tissue showed no necrotic cells and a visibly greater amount of collagen than controls — a plausible, structurally coherent finding rather than just a surface measurement.

What this is, and is not. It is a real, dose-responsive, multi-model animal study with objective endpoints (contraction percentage, tensile strength, histology), which is more rigorous than the great majority of plant-extract wound papers. It is also a single study, from a single laboratory, unreplicated by any independent group, using a purpose-formulated hydrogel — not raw leaf, not latex, not anything resembling the traditional root-paste preparation — and it has not been followed by any human pilot trial. The authors’ own conclusion is appropriately modest: the formulation “showed potential for wound healing and may be studied further in clinical trials,” which is a fair statement of where the evidence actually stands and not yet a treatment.

Back to Table of Contents

The Latex Protease Story: One Mechanism, Two Directions

This is the most mechanistically interesting finding in the whole wound-healing claim, and it is also the clearest example on this page of the evidence doctrine’s point that a benefit and a hazard can come from exactly the same molecular property.

Crape jasmine’s latex contains a family of unusually stable cysteine proteases — enzymes that cut other proteins — that has been studied under the name ervatamins since the late 1990s, using the plant’s older synonym Ervatamia coronaria. Multiple biochemistry groups have purified and structurally characterised individual members of this family: highly stable protease activity from the latex was first reported in 1998, individual proteases named ervatamin A and ervatamin B were purified and characterised in the early 2000s, and a 2008 structural paper in the FEBS Journal placed them formally in the papain-like cysteine protease family — the same broad enzyme class as papain itself, the meat-tenderising enzyme from papaya latex.

In 2021, an Indian biochemistry group purified a roughly 25-kilodalton cysteine protease from crape jasmine latex and tested it directly for haemostatic (blood-clotting-related) activity. The results were specific and quantified: compared with the crude latex enzyme, the purified protease showed a 77.32% enhancement in its ability to induce clot formation, and an 89.86% improvement in its ability to break down an existing blood clot — a plasmin-like activity. It hydrolysed all three chains of human fibrinogen (the protein blood clots are built from). The authors’ own framing was that plant latex proteases “can be utilised as a potential natural agent for wound healing applications” — reasonable, since controlled proteolytic debridement (breaking down dead tissue and old clot material) is a genuine, medically recognised part of how some wounds are treated.

Here is the mechanism that cuts both ways. A papain-like cysteine protease that can digest fibrinogen and hydrolyse tissue protein is, by the same token, an enzyme capable of digesting intact skin and mucous membrane protein if applied undiluted and uncontrolled. Papain itself — the closest well-known relative of the ervatamins — is a recognised skin and mucous-membrane irritant and a known contact allergen at high concentration, which is exactly why meat tenderiser is not used as a skin treatment despite containing a real proteolytic enzyme. The main topic page’s warning that crape jasmine latex is irritating to skin and dangerous in the eye is not a vague family-level caution — it is very plausibly this exact same enzyme family, unregulated in concentration and unbuffered, doing to intact tissue what it did to fibrinogen in a test tube. A benefit and a hazard from one property, described twice.

Back to Table of Contents

Anti-Inflammatory Extract Data

Two studies, thirty years apart, provide direct evidence of topical or systemic anti-inflammatory activity from whole-plant extracts, and one of them is directly relevant to the traditional route of use.

A 1996 Brazilian study working with Ervatamia coronaria found that aqueous and alcoholic extracts, given orally or by injection to rats an hour before a standard carrageenin-induced paw inflammation, produced a significant anti-inflammatory effect; the alcoholic extract also showed analgesic activity and extended pentobarbital-induced sleeping time in the same animals, a classic (if crude) marker of central nervous system depressant activity. The same study isolated coronaridine, heyneanine, voacristine, voacamine and descarbomethoxyvoacamine as the plant’s major alkaloids, alongside several phenolic acids.

More directly relevant to a topical skin claim, a 2013 Indian study applied crape jasmine leaf extract directly to the ear of mice in a croton-oil-induced oedema model — a topical route matching the traditional application far more closely than an oral dose would. The methanol extract dose-dependently inhibited ear swelling, and bioassay-guided fractionation identified a hexane fraction with striking potency (42.1% inhibition at just 0.7 micrograms per square centimetre, versus 48.8% inhibition from the reference drug indomethacin at 90 micrograms per square centimetre — more than a hundredfold higher dose). That comparison is real, but it needs a caveat the paper itself supplies: the most active fraction contained no chemically identified compounds by the methods used. A potent but chemically unidentified active principle is a genuine research lead, not yet a characterised ingredient, and it cannot be dosed, standardised, or checked for purity in any product sold today.

Back to Table of Contents

Antimicrobial Claims, Examined One by One

This is where the literature needs the most careful reading, because four separate studies get folded into a single “antimicrobial” claim on sight, and each one is actually measuring something different.

  1. The zinc oxide nanoparticle study. A 2018 paper used aqueous crape jasmine leaf extract to green-synthesise zinc oxide nanoparticles — the plant’s phytochemicals acted as a reducing and stabilising agent that converts a zinc salt into crystalline ZnO nanocrystals, a standard materials-chemistry technique. The resulting nanoparticles showed real antibacterial activity against Salmonella paratyphi, E. coli and Staphylococcus aureus, and photocatalytic dye-degradation activity under sunlight. Read this precisely: the demonstrated antibacterial agent is the zinc oxide nanoparticle, not the plant extract. Zinc oxide nanoparticles are well documented to be broadly antibacterial regardless of which plant was used as the reducing agent during synthesis — the same result would very plausibly appear using a different leaf extract entirely. This paper is genuine green-chemistry and nanomaterials research; it is not evidence that crape jasmine itself kills bacteria.
  2. The fluconazole-resistance study. In 2021, a phytochemistry group isolated nineteen indole alkaloids from crape jasmine, including eleven newly described compounds (named taberdines), and tested them against a fluconazole-resistant strain of Candida albicans. Several of the alkaloids, combined with a low dose of fluconazole, restored the drug’s effectiveness against the resistant strain. The paper states this explicitly: none of the alkaloids showed any activity against the resistant strain when used alone. This is a real and potentially useful finding about resensitising a drug-resistant pathogen to an existing antifungal — a genuine pharmacological synergist effect — and it is specifically not evidence that the plant, or any of its named alkaloids, is itself an antifungal agent.
  3. The anticariogenic study. A small 2023 Kerala dental-research study tested an ethyl alcoholic extract of crape jasmine leaves against two common tooth-decay bacteria, Streptococcus mutans and Lactobacillus acidophilus, and found substantial antibacterial action, measuring minimum inhibitory and bactericidal concentrations directly against live cultures. This is the one antimicrobial finding in this section that tested the plant extract itself, directly, against live bacteria, with a result in the expected direction. It remains a single small in-vitro study from one laboratory, with no human data and no product recommendation attached — the authors themselves call for further research rather than any clinical claim.
  4. The computational docking study. A 2014 Indian bioinformatics paper used molecular-docking software to predict which of sixty-six low-molecular-weight compounds identified in crape jasmine might bind well to bacterial target proteins in Streptococcus pneumoniae, ranking candidates like apparicine, voacangine and coronaridine by predicted binding energy. This is a computational prediction only. Nothing in this study was synthesised, purified, or tested against a living bacterial culture. It is a legitimate hypothesis-generating exercise for future wet-lab work, and it should never be read as evidence that the plant, or any named compound in it, actually kills S. pneumoniae.

Read together, the honest summary is: one small, real, direct antibacterial finding against oral pathogens; one real synergist effect that requires a co-administered drug and proves nothing about the plant alone; one real nanomaterial finding that is not about the plant’s own antimicrobial activity at all; and one computer prediction that has never been tested. A supplement description reading “clinically shown to fight bacteria and fungi” would be citing all four of these studies while accurately representing none of them.

Back to Table of Contents

Why Raw Latex Is Not a Wound Dressing

It is worth being explicit about the gap between the evidence above and any home use, because the wound-healing and protease data above could easily be misread as license to apply garden latex to a cut.

None of the real evidence in this article supports putting fresh crape jasmine latex on a cut, a burn, or especially an eye. It supports continued laboratory interest in purified, standardised extracts of the plant as a starting point for a future wound-care product — a meaningfully different claim.

What Would Actually Settle This

Human wound-healing trials are not exotic or unusual — they are a routine part of wound-care product development, and naming the standard tools makes clear how far this plant’s evidence base is from them. A real trial would use a validated wound-assessment instrument (such as the Bates-Jensen Wound Assessment Tool or the PUSH tool for pressure injuries), digital planimetry to measure wound-area reduction over time on real patients rather than rat skin, a defined and reproducible extract with a stated concentration, a blinded comparison against standard-of-care dressing, and a clinically meaningful endpoint such as time to complete closure or infection rate. None of that exists for crape jasmine. The 2024 hydrogel study is the first piece of work that could plausibly be scaled into such a trial, because it is the first to use a standardised, reproducible preparation rather than an undefined traditional paste — but it has not yet been.

Back to Table of Contents

Evidence Ledger for This Page

  1. Latex protease (ervatamin) haemostatic/fibrinolytic biochemistry. Tier: well-characterised in isolated, purified form across multiple independent studies since the late 1990s. Real enzymology; never tested as a topical wound treatment in that isolated form.
  2. Standardised hydrogel wound healing (excision, incision, burn). Tier: single recent animal study, dose-responsive, multiple objective endpoints. Unreplicated; no human data.
  3. Topical anti-inflammatory activity (ear-oedema model). Tier: single animal study, real dose-response, most active fraction chemically unidentified.
  4. Anticariogenic activity against oral bacteria. Tier: single small in-vitro study, direct test against live bacteria.
  5. Antifungal resensitisation of drug-resistant Candida. Tier: single study, real but synergist-only — no standalone antifungal activity shown.
  6. Direct antibacterial activity of the plant extract itself (not a synthesised nanomaterial). Tier: thin — only the small dental study measured this directly; the more widely cited nanoparticle result is not actually a test of the plant.
  7. Human efficacy or safety data for any topical preparation of this plant. Tier: absent.

Practical Guidance

Back to Table of Contents

Key Research Papers

Every link below is a PubMed search, built from author names and distinctive title words and confirmed live to return the intended paper before publication — never a bare record number.

  1. Gargate N, Raut S, Kapare H, Shende P, Bhole R. Formulation, characterization and in-vivo evaluation of standardized Tabernaemontana divaricata extract hydrogel for wound healing. Journal of Ayurveda and Integrative Medicine, 2024. Find on PubMed.
  2. Singh MK, Rajagopalan A, Tanimu H, Sukumaran BO. Purification, characterization and fibrino(geno)lytic activity of cysteine protease from Tabernaemontana divaricata latex. 3 Biotech, 2021. Find on PubMed.
  3. Ghosh R, et al. Structural insights into the substrate specificity and activity of ervatamins, the papain-like cysteine proteases from a tropical plant, Ervatamia coronaria. The FEBS Journal, 2008. Find on PubMed.
  4. Jain S, Sharma P, Ghule S, Jain A, Jain N. In vivo anti-inflammatory activity of Tabernaemontana divaricata leaf extract on male albino mice. Chinese Journal of Natural Medicines, 2013. Find on PubMed.
  5. Henriques AT, Melo AA, Moreno PR, Ene LL, Henriques JA, Schapoval EE. Ervatamia coronaria: chemical constituents and some pharmacological activities. Journal of Ethnopharmacology, 1996. Find on PubMed.
  6. Raja A, Ashokkumar S, Pavithra Marthandam R, et al. Eco-friendly preparation of zinc oxide nanoparticles using Tabernaemontana divaricata and its photocatalytic and antimicrobial activity. Journal of Photochemistry and Photobiology B, 2018. Nanomaterial evidence, not herbal evidence — see above. Find on PubMed.
  7. John MK, Cheriyan DZ. Anticariogenic potential of Tabernaemontana divaricata. Indian Journal of Dental Research, 2023. Find on PubMed.
  8. Zhang Y, Bai X, Yuwen HS, Guo LL, Liu JW, Hao XJ. Alkaloids from Tabernaemontana divaricata combined with fluconazole to overcome fluconazole resistance in Candida albicans. Bioorganic Chemistry, 2021. Synergist only. Find on PubMed.
  9. Gogoi RR, Gogoi D, Bezbaruah RL. Virtual screening of compounds from Tabernaemontana divaricata for potential anti-bacterial activity. Bioinformation, 2014. Computational docking only. Find on PubMed.
  10. Bhadane BS, Patil MP, Maheshwari VL, Patil RH. Ethnopharmacology, phytochemistry, and biotechnological advances of family Apocynaceae: a review. Phytotherapy Research, 2018. Find on PubMed.

Back to Table of Contents

Connections

Back to Table of Contents